STEVE INSKEEP, Host:
It's MORNING EDITION from NPR News. I'm Steve Inskeep.
RENEE MONTAGNE, Host:
NPR's Julie Rovner has the story.
JULIE ROVNER: Back in May, President Obama announced with much fanfare a deal he cut with many of Washington's top health care players, including groups representing doctors, drug makers, hospitals, and health insurers.
BARACK OBAMA: Over the next 10 years, from 2010 to 2019, they are pledging to cut the rate of growth of national health care spending by 1.5 percentage points each year, an amount that's equal to over $2 trillion dollars.
ROVNER: Later, some of those groups would cut more specific deals offering voluntary cuts in exchange for lawmakers agreeing not to cut their industries even deeper as part of the health overhaul. The deals were intended to prevent past enemies of the overhaul effort from launching multi-million dollar lobbying and advertising campaigns against the bills, and the deals have pretty much succeeded. But now patient advocates and others say lawmakers have given away too much to the health care special interests.
RALPH NEAS: Our coalition has not embraced one bill at this time, and that's because of cost containment.
ROVNER: More specifically, the lack of cost containment. Ralph Neas is CEO of the National Coalition on Health Care, a nonpartisan group. He's more than a bit skeptical of the promises made by the health industry groups.
NEAS: We're going to cut $2 trillion voluntarily from our costs over the next 10 years. We said that's a magnificent commitment, but I come from a civil rights background. Voluntary efforts don't work. There's got to be some enforceability.
ROVNER: Neas says a case in point is the $80 billion pledged by the brand name pharmaceutical industry, which stands to make lots more money from lots more newly insured patients if a major health overhaul bill becomes law.
NEAS: If they're going to get these hundreds of billions of dollars, trillions of dollars over the next 10 or 20 years, they should be paying more than $80 billion.
ROVNER: Many patient and consumer groups are particularly unhappy about provisions now included in both House and Senate health bills that would give brand name makers of expensive biotech drugs 12 additional years on the market before cheaper generic copies could be made and sold. Former Republican congressman Bill Thomas is among them.
BILL THOMAS: It is outrageous to provide them 12 years, just outrageous.
ROVNER: That's not what the drug industry says, of course. Ken Johnson is senior vice president of PhRMA, the brand name drug company's industry group.
KEN JOHNSON: Unfortunately, critics ignore the tremendous costs and challenges involved in researching and developing such complex cutting edge medicines. Development costs for innovative biologics can exceed $1.2 billion plus an additional $450 million to build specialized manufacturing facilities.
ROVNER: Meanwhile, patients who need expensive biotech drugs are caught in the middle. Anne Collins(ph) has psoriatic arthritis, a complication of psoriasis. She says the biologic drug she takes is nothing short of a miracle.
ANNE COLLINS: I probably wouldn't be here today because I wouldn't be able to walk if I didn't take this drug.
ROVNER: But it costs $2,000 to fill each prescription, and while her insurance pays most of the cost for now...
COLLINS: I blew through all of my benefits last year, and I will do so again.
ROVNER: Since her policy only covers $40,000 worth of drugs each year. But there won't be a cheaper generic version of her drug for years, if ever. Former Congressman Thomas says since both the House and Senate bills now have 12-year patent extensions for the biotech drugs, there's only one way to force the drug makers to bargain.
THOMAS: You've got to put them at risk. You've got to move amendments that put them at risk, so when you close the door and you talk about, you want to deal with the 12 years, they don't thumb their nose at you, they actually see what their risk is.
ROVNER: Julie Rovner, NPR News, Washington.
NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.